Alaunos Therapeutics (TCRT) 10-K2019 FY Annual report

Filed: 2 Mar 20, 4:03pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accuracy, administrationof, afund, alloTCR, amountof, andBeneficial, andscalable, andsubsequent, apotent, arepursuing, ArsenalBio, asControlled, astargeting, autoTCR, baseline, believeControlled, benchmark, bleeding, BMT, borrow, borrowing, buildout, cemiplimab, choice, Circuit, cleared, ClinicalDevelopment, combinationof, combinationwith, compensatory, compliant, conditionallyproduce, customary, de, deficiency, developingControlled, EGFR, encourageuse, expresshuman, expressionof, GMP, Gorilla, Hadfield, havetested, inBlood, inClinical, incompetent, incremental, indefinitely, indemnification, India, inScience, intravenously, Iovance, Istari, Karyopharm, lab, left, libraryof, lieu, Lyell, Main, manufacturedusing, match, matching, membrane, MRI, multifocal, multitude, nonfinancial, Northwest, Novocure, Obsidian, ofControlled, ofin, ofrecombinant, ofTCR, online, Optune, ourcontrolled, PACT, partly, PB, PBMC, PGEN, potentialof, PrincipalAccounting, productionof, proper, Protheragen, pseudoprogression, reevaluate, reliant, remanded, rolling, Sath, Satyavrat, Schematic, Shukla, sixty, sublicensee, subscription, substudy, surgical, survivein, swelling, Takeda, thata, thatControlled, thelowest, Therecombinant, thisway, titledBeneficial, titledProposal, tocause, todeliver, toevaluate, Torque, transcription, transcriptional, trialof, unifocal, unilaterally, unpatentable, unqualified, upheld, useof, usinga, vendor, VIE, withRegeneron, withSleeping, worse

Removed: aberrant, add, alive, amending, amortized, andStock, attestation, bifurcated, clinic, collateral, column, constructing, consume, dilution, diversity, dosed, double, engineer, escalation, evolving, executed, explore, favorably, feature, forin, hospital, importing, indibulin, Indonesia, inventory, issuable, Juno, landlord, LLP, Malaysia, nanosuspension, Neon, noncash, NY, organoarsenic, poster, predecessor, preliminary, proportion, pursued, redemption, representing, restatement, RSM, San, Singapore, structure, substance, subtenant, sufficiency, sustainedin, systemic, Thailand, titledStock, today, towardsin, underRule, vivopersistence, voting, York, Zealand

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated TCRT transcripts

TCRT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of ZIOPHARM Oncology, Inc. (the “Company”) on Form10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Laurence J.N. Cooper, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Laurence J.N. Cooper

Laurence J.N. Cooper, M.D., Ph.D.

Chief Executive Officer
(Principal Executive Officer)
March 2, 2020